Clinical Trial

Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:

Study acronym: ESTANVO
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-04; most recent amendment 2025-10-03.
Status change: Not Yet Recruiting → Recruiting 2025-05-02
Trial Details
NCT Number NCT06817161
Lead Sponsor Centre Francois Baclesse
Conditions Ovarian Carcinoma, First Line Chemotherapy, Digestive System Disorders
Enrollment 116 participants
Start Date 2025-04-30
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-07